Leukemia and Lymphoma Society, Forma Therapeutics to Advance Blood Cancer Rxs to Clinic

Jul 22, 2009

Premium

Non-profit disease foundation the Leukemia and Lymphoma Society and drug-discovery startup Forma Therapeutics this week announced a partnership to accelerate the development of therapeutic research projects in LLS' pipeline.

Under the collaboration, LLS will select ten small molecule candidates deemed to have the best chance of quickly advancing to clinical trials from its portfolio of grant-funded academic research projects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Silencing for Preeclampsia

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

Settlement Expected in Duke Case

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

This Week in PNAS

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

Something Different

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Featured White Papers

Sampling for Optimal cfDNA Extraction

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Nov

27

Featured Webinar

Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Nov

29

Featured Webinar

Glass or Polymer? A Comparison for Use in In Vitro Diagnostic Biochips

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec

04

Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Main menu